GlaxoSmithKline may have closed one chapter in a saga of corruption allegations by accepting a $489 million fine in China, but the drugmaker has its work cut out to win back skeptical investors.
Andrew Witty
Breaking News
Subscribe to VCpost newsletter
Most Popular
- American Millionaire Charged in Brutal Murders of Canadian Tycoon and His Partner in Dominica Denied Bail
- SSDI Payment April 2024: Who Will Receive Social Security Benefits Today?
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Tesla Spends $200,000 in Promoting Elon Musk's Social Media Platform X Following Mention of 'Minimal Advertising Efforts'
- Michigan Family Sues Wendy's for $20 Million After 11-Year-Old Girl Suffered Deadly E.Coli Infection
- Brazilian Woman Wheels Her Dead Uncle Into the Bank to Withdraw Loan in His Name
- Australian Farmer Prepares Grave of 3,000 Sheep After Failing to Find Buyer
- Sheetz Convenience Store Accused of Racial Discrimination After Denying Employment of Black, Mixed-Race, and Native American Applicants
